<DOC>
	<DOCNO>NCT00856375</DOCNO>
	<brief_summary>This study evaluate whether NKTR-102 , investigational drug anti-tumor effect patient colorectal cancer . This study also evaluate safety anti-tumor activity NKTR-102 compare irinotecan , cancer drug approve use US treatment patient certain type colorectal cancer .</brief_summary>
	<brief_title>NKTR-102 Versus Irinotecan Patients With Second-Line , Irinotecan-Na√Øve , KRAS Mutant , Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>metastatic colorectal cancer tumor kras mutation More 1 prior regimen treatment metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Colorectal cancer , second line</keyword>
</DOC>